SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN

被引：0
|
作者：
Ramirez de Arellano, A. [1 ]
Morales, C. [2 ]
De Luis, D. [3 ]
Ferrario, M. G. [4 ]
Lizan, L. [4 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Hosp Virgen de la Macarena, Seville, Spain
[3] Hosp Rio Hortega, Valladolid, Spain
[4] Outcomes10, Castellon de La Plana, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB63
引用
收藏
页码：A343 / A343
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in an Italian setting. A meta-analysis
    Aristides, M.
    Kotchie, R.
    Nielsen, S.
    Aagren, M.
    Valentine, W. J.
    Goodall, G.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
  • [22] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Nikolajsen, Annie
    Shafie, Asrul Akmal
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
  • [23] SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETES
    Langer, J.
    Wolden, M. L.
    Shimoda, S.
    Sato, M.
    Araki, E.
    [J]. VALUE IN HEALTH, 2018, 21 : S128 - S129
  • [24] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
  • [25] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
    Kostyuk, A.
    Akanov, A.
    Almadiyeva, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
  • [26] Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes
    Umpierrez, Guillermo E.
    Hor, Tiffany
    Smiley, Dawn
    Temponi, Angel
    Umpierrez, Denise
    Ceron, Miguel
    Munoz, Christina
    Newton, Christopher
    Peng, Limin
    Baldwin, David
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02): : 564 - 569
  • [27] Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia
    Pedersen-Bjergaard, Ulrik
    Kristensen, Peter Lommer
    Norgaard, Kirsten
    Perrild, Hans
    Jensen, Tonny
    Thorsteinsson, Birger
    Nikolajsen, Annie
    Tarnow, Lise
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (10) : 1719 - 1725
  • [28] Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes
    Smeeton, F.
    Moradie, F. Shojaee
    Jones, R. H.
    Westergaard, L.
    Haahr, H.
    Umpleby, A. M.
    Russell-Jones, D. L.
    [J]. DIABETOLOGIA, 2009, 52 (11) : 2317 - 2323
  • [29] Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes
    F. Smeeton
    F. Shojaee Moradie
    R. H. Jones
    L. Westergaard
    H. Haahr
    A. M. Umpleby
    D. L. Russell-Jones
    [J]. Diabetologia, 2009, 52 : 2317 - 2323
  • [30] Long-term clinical outcomes of insulin detemir versus NPH for type 1 diabetes patients in Spain
    Kotchie, R.
    Aagren, M.
    Nielsen, S.
    Valentine, W. J.
    Goodall, G.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A273 - A273
12345